ORAGENICS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
OGEN$0.34-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
| Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | |
| Balances at December 31, 2024 | 419,003 | $419 | 7,488,692 | $— | $216,573,868 | $(216,786,172) | $(211,885) |
| Compensation expense relating to options | — | — | — | — | 17,706 | — | 17,706 |
| Compensation expense recapture relating to options | — | — | — | — | (86,470) | — | (86,470) |
| Sale of Common Stock | 258,849 | 259 | — | — | 2,633,931 | — | 2,634,190 |
| Conversion of prefunded warrants to common stock | 37,990 | 38 | — | — | 1,102 | — | 1,140 |
| Issuance of Series G Preferred Stock | — | — | 1,000,000 | — | — | — | — |
| Net loss | — | — | — | — | — | (2,216,993) | (2,216,993) |
| Balances at March 31, 2025 | 715,843 | $716 | 8,488,692 | $— | $219,140,137 | $(219,003,165) | $137,688 |
| Reverse split fractional shares issued | 107,084 | 107 | — | — | (107) | — | — |
| Compensation expense relating to options | — | — | — | — | 6,779 | — | 6,779 |
| Compensation expense recapture relating to options | — | — | — | — | (147) | — | (147) |
| Cancellation of Series G Preferred Stock | — | — | (1,000,000) | — | — | — | — |
| Net loss | — | — | — | — | — | (2,272,035) | (2,272,035) |
| Balances at June 30, 2025 | 822,927 | $823 | 7,488,692 | $— | $219,146,662 | $(221,275,200) | $(2,127,715) |
| Compensation expense relating to options | — | — | — | — | 6,040 | — | 6,040 |
| Sale of Series H Preferred Stock and warrants | — | — | 660,000 | — | 15,019,700 | — | 15,019,700 |
| Conversion of Series H Preferred Stock into common stock | 3,304,246 | 3,304 | (227,878) | — | (3,304) | — | — |
| Net loss | — | — | — | — | — | (3,066,589) | (3,066,589) |
| Balances at September 30, 2025 | 4,127,173 | $4,127 | 7,920,814 | $— | $234,169,098 | $(224,341,789) | $9,831,436 |
| Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at December 31, 2023 | 102,690 | $103 | 16,955,197 | $1,592,723 | $207,793,582 | $(206,218,254) | $3,168,154 |
| Compensation expense relating to option issuances | — | — | — | — | 69,344 | — | 69,344 |
| Sale of Common Stock | 46,667 | 47 | — | — | 1,838,554 | — | 1,838,601 |
| Net loss | — | — | — | — | — | (2,450,833) | (2,450,833) |
| Balances at March 31, 2024 | 149,357 | $150 | 16,955,197 | $1,592,723 | $209,701,480 | $(208,669,087) | $2,625,266 |
| Compensation expense relating to option issuances | — | — | — | — | 58,220 | — | 58,220 |
| Sale of Common Stock | 36,667 | 37 | — | — | 947,963 | — | 948,000 |
| Net loss | — | — | — | — | — | (2,305,090) | (2,305,090) |
| Balances at June 30, 2024 | 186,024 | $187 | 16,955,197 | $1,592,723 | $210,707,663 | $(210,974,177) | $1,326,396 |
| Compensation expense relating to option issuances | — | — | — | — | 330,802 | — | 330,802 |
| Sale of Common Stock | 126,895 | 127 | — | — | 3,883,132 | — | 3,883,259 |
| Net loss | — | — | — | — | — | (2,462,870) | (2,462,870) |
| Balances at September 30, 2024 | 312,919 | $314 | 16,955,197 | $1,592,723 | $214,921,597 | $(213,437,047) | $3,077,587 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.